148 related articles for article (PubMed ID: 27554637)
1. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents.
Chiricozzi A; Romanelli M; Saraceno R; Torres T
Expert Opin Drug Saf; 2016 Dec; 15(12):1653-1659. PubMed ID: 27554637
[TBL] [Abstract][Full Text] [Related]
2. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.
Saunte DM; Mrowietz U; Puig L; Zachariae C
Br J Dermatol; 2017 Jul; 177(1):47-62. PubMed ID: 27580411
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
[TBL] [Abstract][Full Text] [Related]
4. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases.
Wasilewska A; Winiarska M; Olszewska M; Rudnicka L
Postepy Dermatol Alergol; 2016 Aug; 33(4):247-52. PubMed ID: 27605893
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab for the treatment of psoriasis.
Galluzzo M; D'adamio S; Bianchi L; Talamonti M
Expert Rev Clin Immunol; 2016 Dec; 12(12):1255-1271. PubMed ID: 27718760
[TBL] [Abstract][Full Text] [Related]
7. Brodalumab: First Global Approval.
Greig SL
Drugs; 2016 Sep; 76(14):1403-12. PubMed ID: 27577550
[TBL] [Abstract][Full Text] [Related]
8. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
Papp KA; Lebwohl MG
J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
[TBL] [Abstract][Full Text] [Related]
9. IL-17A causes depression-like symptoms via NFκB and p38MAPK signaling pathways in mice: Implications for psoriasis associated depression.
Nadeem A; Ahmad SF; Al-Harbi NO; Fardan AS; El-Sherbeeny AM; Ibrahim KE; Attia SM
Cytokine; 2017 Sep; 97():14-24. PubMed ID: 28570931
[TBL] [Abstract][Full Text] [Related]
10. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks.
Huang YYM; Ruth JS; Hsu S
J Am Acad Dermatol; 2016 Oct; 75(4):e169. PubMed ID: 27646769
[No Abstract] [Full Text] [Related]
11. Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Attia A; Abushouk AI; Ahmed H; Gadelkarim M; Elgebaly A; Hassan Z; Abdel-Daim MM; Negida A
Clin Drug Investig; 2017 May; 37(5):439-451. PubMed ID: 28197901
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Secukinumab for Moderate-to-Severe Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies.
Kircik L; Fowler J; Weiss J; Meng X; Guana A; Nyirady J
Dermatol Ther (Heidelb); 2016 Dec; 6(4):627-638. PubMed ID: 27573260
[TBL] [Abstract][Full Text] [Related]
14. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.
Warren RB; Brnabic A; Saure D; Langley RG; See K; Wu JJ; Schacht A; Mallbris L; Nast A
Br J Dermatol; 2018 May; 178(5):1064-1071. PubMed ID: 29171861
[TBL] [Abstract][Full Text] [Related]
15. Guselkumab for psoriasis: a critical appraisal of Phase III studies.
Yiu ZZ; Warren RB
Immunotherapy; 2018 Jan; 10(1):67-75. PubMed ID: 29043884
[TBL] [Abstract][Full Text] [Related]
16. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.
Matusiak Ł; Szczęch J; Bieniek A; Nowicka-Suszko D; Szepietowski JC
J Am Acad Dermatol; 2017 Apr; 76(4):670-675. PubMed ID: 28041632
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
de Carvalho AV; Duquia RP; Horta BL; Bonamigo RR
Drugs R D; 2017 Mar; 17(1):29-51. PubMed ID: 27838901
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.
Wei M; Duan D
Drug Des Devel Ther; 2016; 10():2771-2777. PubMed ID: 27672309
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
